Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Assay identifies neurological disease candidates
November 2017
SHARING OPTIONS:

PITTSBURGH—An oral presentation made by Cognition Therapeutics Inc. at this year’s American Chemical Society National Meeting featured the company’s phenotypic neuronal assay, which Cognition Therapeutics says has successfully identified orally available, highly brain-penetrant small-molecule drug candidates for Alzheimer’s and other neurological diseases. Cognition Therapeutics discovered its lead candidate, CT1812, with the neuronal assay.
 
“Our proprietary phenotypic neuronal assay is a powerful engine for discovering small-molecule drug candidates that act against toxic proteins implicated in neurological diseases,” said Dr. Susan Catalano, chief scientific officer. “By employing this assay, we have identified structurally distinct compounds that have been shown to protect synapses from the neuronal toxicity of amyloid beta (Aß) oligomers. Among these was CT1812, a specific antagonist of the sigma-2 receptor complex.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.